MedTrace Logo

Trial to Evaluate the Efficacy and Safety of KM-819 Treatment to Slow the Progression of Multiple System Atrophy (MSA)

NCT05695378 · Status: TERMINATED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 68

Last updated 2024-09-19

No results posted yet for this study

Summary

This trial will the efficacy of KM-819 compared to placebo in subjects with MSA for slowing the progression of MSA.

Conditions

Interventions

DRUG

KM-819

Subjects will receive KM-819 400 mg orally daily.

DRUG

Placebo

Subjects will receive Placebo orally daily.

Sponsors & Collaborators

  • Parexel

    collaborator INDUSTRY

  • Kainos Medicine Inc.

    lead INDUSTRY

Principal Investigators

  • Chong Sik Lee · PI

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
DOUBLE
Model
PARALLEL

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-02-27
Primary Completion
2024-08-19
Completion
2024-08-19

Countries

  • South Korea

Study Locations

More Related Trials

Entities

Drugs
Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05695378 on ClinicalTrials.gov